4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management
Key Takeaways
- Diabetes Canada criteria diagnose diabetes with FPG ≥ 7.0 mmol/L, 2h 75g OGTT ≥ 11.1 mmol/L, HbA1c ≥ 6.5%, or random plasma glucose ≥ 11.1 mmol/L with classic symptoms.
- Standard HbA1c target is ≤ 7.0% for most adults; individualized targets range from ≤ 6.5% (for microvascular protection in low-hypoglycemia-risk patients) to 7.1%–8.5% (in frail elderly or those with severe hypoglycemia history).
- In patients with T2D and established ASCVD, CKD (eGFR 20–60 mL/min/1.73m² or UACR > 3 mg/mmol), or Heart Failure, SGLT2 inhibitors or GLP-1 receptor agonists are indicated with proven cardiorenal benefit INDEPENDENT of baseline HbA1c.
- Emergency DKA management requires IV Normal Saline resuscitation, checking serum potassium BEFORE insulin initiation (hold insulin if K+ < 3.3 mmol/L), IV regular insulin infusion (0.1 units/kg/h), and adding D5W when glucose reaches 14.0 mmol/L.
- SGLT2 inhibitor therapy can precipitate euglycemic DKA (blood glucose < 11.1 mmol/L with high anion gap metabolic acidosis and ketonemia), requiring immediate SGLT2i cessation and standard DKA protocol.
4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management
Diagnostic Criteria & Screening Guidelines
According to Diabetes Canada Clinical Practice Guidelines, screening for Type 2 Diabetes (T2D) should be performed every 3 years in all adults aged ≥ 40 years, or more frequently in individuals with risk factors (e.g., first-degree relative with T2D, high-risk ethnicity, metabolic syndrome, history of gestational diabetes, or corticosteroid use).
Diagnostic Thresholds Table
| Diagnostic Test | Normal | Prediabetes | Diabetes Mellitus |
|---|---|---|---|
| Fasting Plasma Glucose (FPG) | < 5.6 mmol/L | 5.6 – 6.9 mmol/L (Impaired Fasting Glucose) | ≥ 7.0 mmol/L |
| 2-Hour 75g OGTT | < 7.8 mmol/L | 7.8 – 11.0 mmol/L (Impaired Glucose Tolerance) | ≥ 11.1 mmol/L |
| Glycated Hemoglobin (HbA1c) | < 5.7% | 6.0 – 6.4% (High Risk for Diabetes) | ≥ 6.5% |
| Random Plasma Glucose | N/A | N/A | ≥ 11.1 mmol/L (with symptoms) |
Note: In the absence of symptomatic hyperglycemia (polyuria, polydipsia, weight loss), a single abnormal laboratory result must be confirmed by repeat testing on a separate day.
Individualized Glycemic Targets
Diabetes Canada emphasizes individualized HbA1c targets based on patient characteristics:
- HbA1c ≤ 7.0%: Standard target for most non-pregnant adults with Type 1 or Type 2 Diabetes to reduce microvascular (retinopathy, nephropathy, neuropathy) and macrovascular complications.
- HbA1c ≤ 6.5%: Recommended in select newly diagnosed patients with long life expectancy, low hypoglycemia risk, and absence of cardiovascular disease, to achieve long-term microvascular risk reduction.
- HbA1c 7.1% – 8.5%: Individualized target for patients with:
- Severe hypoglycemia history or hypoglycemia unawareness.
- Limited life expectancy.
- Advanced microvascular or macrovascular disease.
- Frail elderly status or high functional dependency.
- Glycemic Range Targets: Fasting/preprandial glucose 4.0 – 7.0 mmol/L; 2-hour postprandial glucose 5.0 – 10.0 mmol/L (5.0 – 8.0 mmol/L if HbA1c target is ≤6.5%).
Pharmacotherapy & Organ-Protection Framework
First-line therapy for all patients with T2D includes healthy behavior interventions (dietary optimization, exercise) combined with Metformin (unless contraindicated, e.g., eGFR < 30 mL/min/1.73m² due to lactic acidosis risk).
The Cardiorenal Paradigm Shift
Regardless of baseline HbA1c or current metformin use, Diabetes Canada guidelines mandate evaluating for clinical cardiorenal conditions and initiating organ-protective agents immediately:
- Established ASCVD (prior MI, stroke, PAD): Add an SGLT2 inhibitor (Empagliflozin, Dapagliflozin, Canagliflozin) OR a GLP-1 receptor agonist (Semaglutide, Liraglutide, Dulaglutide) with proven cardiovascular outcome reduction.
- Heart Failure (HFrEF or HFpEF): Add an SGLT2 inhibitor (Empagliflozin, Dapagliflozin) to reduce heart failure hospitalizations and CV mortality.
- Chronic Kidney Disease (eGFR 20–60 mL/min/1.73m² or UACR > 3.0 mg/mmol): Add an SGLT2 inhibitor (Empagliflozin, Dapagliflozin, Canagliflozin) to slow CKD progression, reduce ESKD, and lower CV mortality.
Antihyperglycemic Class Comparison
| Class & Examples | Hypoglycemia Risk | Weight Impact | Cardiorenal Benefit | Key Clinical Considerations |
|---|---|---|---|---|
| Metformin | Negligible | Neutral / Loss | Moderate CV safety | First-line; stop if eGFR < 30 mL/min/1.73m² |
| SGLT2 Inhibitors<br/>(Empagliflozin, Dapagliflozin) | Negligible | Loss (2-3 kg) | Decreased HF hospitalization, decreased CKD progression, decreased CV death | Mycotic genital infections, volume depletion, Euglycemic DKA |
| GLP-1 RAs<br/>(Semaglutide, Liraglutide) | Negligible | Significant Loss | Decreased MACE, stroke, CV death | Nausea/vomiting; avoid in personal/family history of MTC / MEN 2 |
| DPP-4 Inhibitors<br/>(Sitagliptin, Linagliptin) | Negligible | Neutral | Neutral | Saxagliptin increases HF risk; Linagliptin requires no renal dose adjustment |
| Sulfonylureas<br/>(Gliclazide, Glyburide) | Moderate – High | Gain | Neutral | High hypoglycemia risk; Gliclazide MR preferred over glyburide |
| Insulin<br/>(Glargine, Degludec, Aspart) | High | Gain | Neutral | Indicated if severe hyperglycemia (HbA1c ≥ 1.5% above target) or symptomatic |
Acute Metabolic Emergencies: DKA vs HHS
| Feature | Diabetic Ketoacidosis (DKA) | Hyperosmolar Hyperglycemic State (HHS) |
|---|---|---|
| Primary Population | Type 1 Diabetes (primarily) | Type 2 Diabetes (elderly, dehydrated, infection) |
| Serum Glucose | > 14.0 mmol/L (or normal in Euglycemic DKA) | > 30.0 mmol/L |
| Arterial / Venous pH | < 7.30 (Severe < 7.00) | > 7.30 |
| Serum Bicarbonate | < 18 mmol/L | > 18 mmol/L |
| Anion Gap | Elevated (> 10–12 mmol/L) | Normal or mildly elevated |
| Serum Ketones | Strongly Positive (Beta-hydroxybutyrate > 3.0 mmol/L) | Absent or trace |
| Serum Osmolality | Variable | Markedly Elevated (> 320 mOsm/kg) |
Step-by-Step DKA Management Protocol
- Fluid Resuscitation: Administer 0.9% Normal Saline 1.0–1.5 L IV in the 1st hour. Switch to 0.45% NaCl if corrected serum sodium is normal or elevated.
- Potassium Check (CRITICAL): Check K+ BEFORE initiating IV insulin!
- K+ < 3.3 mmol/L: HOLD insulin! Administer IV KCl 20–30 mEq/h until K+ > 3.3 mmol/L to prevent fatal arrhythmias.
- K+ 3.3–5.0 mmol/L: Give regular insulin AND add 20–30 mEq KCl per liter of IV fluid to maintain serum K+ 4.0–5.0 mmol/L.
- K+ > 5.0 mmol/L: Initiate IV insulin infusion; monitor serum K+ every 1–2 hours without adding potassium to IV fluids.
- Insulin Infusion: Administer regular insulin IV at 0.1 units/kg/h. Target a steady glucose drop of 3.0–4.0 mmol/L per hour.
- Addition of Dextrose: When serum glucose reaches 14.0 mmol/L, add 5% Dextrose (D5W) to IV fluids while CONTINUING insulin infusion at 0.05–0.1 units/kg/h. Continue IV insulin until the anion gap closes (< 10–12 mmol/L), bicarbonate is ≥ 18 mmol/L, and pH > 7.30.
Inpatient Glycemic Control & Complication Screening
- Inpatient Targets: Non-critical ward patients target preprandial glucose 6.0–8.0 mmol/L and random glucose < 10.0 mmol/L. Sliding-scale insulin monotherapy is ineffective and strongly discouraged. Use a structured Basal-Bolus-Correction insulin regimen.
- Annual Complication Screening:
- Nephropathy: Annual Urine Albumin-to-Creatinine Ratio (UACR) plus eGFR. Normal UACR < 2.0 mg/mmol; Microalbuminuria 2.0–20.0 mg/mmol; Overt nephropathy > 20.0 mg/mmol.
- Retinopathy: Dilated eye examination every 1–2 years.
- Neuropathy: 10-g Semmes-Weinstein monofilament test annually.
- Cardiovascular Statin Indication: Statin therapy is indicated for all adults with diabetes who are age ≥ 40, OR have established cardiovascular disease, OR have microvascular disease, regardless of baseline LDL-C (target LDL-C < 2.0 mmol/L).
[!WARNING] MCCQE1 High-Yield Trap: Euglycemic DKA with SGLT2 Inhibitors SGLT2 inhibitors (empagliflozin, dapagliflozin) can trigger Euglycemic DKA during times of physiological stress, surgery, acute infection, or carbohydrate restriction. Serum glucose is characteristically < 11.1 mmol/L (often 7.0–10.0 mmol/L), masking the diagnosis! Key features: High anion gap metabolic acidosis with positive serum beta-hydroxybutyrate. Management: Stop SGLT2i immediately, administer IV fluids, IV regular insulin, AND IV dextrose (D5W) simultaneously.
A 62-year-old male with Type 2 Diabetes and documented ischemic heart disease (prior myocardial infarction 2 years ago) presents for routine follow-up. His current medications include Metformin 1000 mg BID. Laboratory work shows HbA1c 7.2%, eGFR 54 mL/min/1.73m², and UACR 4.2 mg/mmol. According to Diabetes Canada guidelines, what is the most appropriate next step in pharmacotherapy?
A 22-year-old female with Type 1 Diabetes is brought to the ED lethargic and vomiting. Vitals: BP 94/58 mmHg, HR 122/min, RR 28/min (Kussmaul breathing). Labs: Glucose 24.5 mmol/L, Arterial pH 7.12, Serum Bicarbonate 9 mmol/L, Anion Gap 22 mmol/L, and Potassium 3.1 mmol/L. What is the mandatory immediate first step in her management?
A 58-year-old male with T2D taking Dapagliflozin presents with nausea, abdominal pain, and deep breathing. Blood glucose is 9.8 mmol/L. Arterial blood gas shows pH 7.22, bicarbonate 12 mmol/L, and anion gap 18 mmol/L. Serum beta-hydroxybutyrate is 4.5 mmol/L. What condition does this patient have, and what is the immediate intervention?